Research programme: anticancer therapeutics - Rexahn

Drug Profile

Research programme: anticancer therapeutics - Rexahn

Alternative Names: RX-0183; RX-1792; RX-1834; RX-5315; RX-8243

Latest Information Update: 16 Jul 2015

Price : $50

At a glance

  • Originator Rexahn Pharmaceuticals
  • Class Isoquinolines; Piperazines; Quinazolines; Quinoxalines; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Microtubule protein inhibitors; Proto oncogene protein c-akt inhibitors; Proto oncogene proteins c fos inhibitors; RNA helicase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 14 Jul 2015 Rexahn has patent protection for CPMA drug delivery technology in Japan
  • 17 Jan 2012 This programme is still in active development
  • 17 Jan 2012 Research programme: anticancer therapeutics - Rexahn is available for licensing as of 17 Jan 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top